August 15, 2016

Advanced Silicone Hydrogel Technology Results in Better Overall Comfort1

PLEASANTON, Calif., August 15, 2016 — Illustrating its commitment to provide eye care practitioners and their patients with advanced contact lens technology in every modality, CooperVision, Inc. today announced the launch of Avaira Vitality™ in the United States. This superior version of its popular Avaira® two-week contact lenses provides multiple benefits through a new silicone hydrogel material.

Avaira Vitality™ sphere and toric lenses are made from a new material (fanfilcon A), which features a higher water content (55%) as well as a high level of oxygen permeability and transmissibility, resulting in overall comfort for wearers. UV protection has also been improved to Class I—the top rating—which means the lenses now block more than 90 percent of UVA and 99 percent of UVB rays.

“Monthly lenses remain the most prescribed modality in the U.S., and while we are currently seeing strong growth in the 1-day market, it’s important to remember that the two-week modality is the second largest market segment. These lenses continue to present significant opportunity for practices, largely due to their affordable, entry-level price point,” said Jerry Warner, President, North America, CooperVision.

“Two-week wearers should benefit from the latest advances in silicone hydrogel technology. CooperVision aims to provide a lens for every eye through our partnership with eye care providers, and Avaira Vitality™ will be an important part of the company’s offerings. Our long-standing dedication to investing in our lens portfolio’s depth and breadth enables practitioners to fit a greater number of patients, increasing satisfaction and helping grow their businesses.”

Avaira Vitality™ allows for easy refits of current Avaira® wearers. In testing, 94 percent of Avaira® wearers refit with Avaira Vitality™ preferred the new lens.1

“Based on this study, we expect current Avaira® wearers to transition seamlessly to Avaira Vitality™, without any need for additional chair time,” said Michele Andrews, OD, Senior Director of Professional and Academic Affairs, North America, CooperVision. “The new lens is overwhelmingly preferred for both visual acuity and comfort, while offering the same lens design that so many patients already love.”

Avaira Vitality™ sphere lenses feature powers from +8.00D to -12.00D; a modulus of 0.6MPa; a DK of 90; a Dk/t of 110; a base curve of 8.4mm; and a diameter of 14.2mm.

Like its predecessor, Avaira Vitality™ toric lenses feature CooperVision’s revolutionary toric technology—Optimized Ballast Design—which provides stability and optimal visual acuity. They will be available in a power range of +8.00D to -10.000D, with cylinder options of 0.75D, 1.25D, 1.75D, and 2.25D in axes from 10° to 180° in 10° steps. They have a modulus of 0.6MPa, a DK of 90, and a Dk/t of 82. The base curve is 8.5mm and the diameter is 14.5mm.

CooperVision will begin distribution of Avaira Vitality™ sphere fit sets and lenses in the U.S. this August. Avaira Vitality™ toric will be available beginning in December in a limited parameter range.  The full power range is planned for 2017.

Avaira Vitality™ lenses are currently available in 6-pack cartons.

For more information, visit

About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market-leading products and treatment options to improve the delivery of health care to women. Headquartered in Pleasanton, CA, Cooper has approximately 10,000 employees with products sold in over 100 countries. For more information, please visit

1 Data on file.

Media Contact

Mike McDougall
McDougall Communications for CooperVision, Inc. or 585-434-2150